A phase I study of veliparib (ABT-888) in combination with low-dose fractionated whole abdominal radiation therapy in patients with advanced solid malignancies and peritoneal carcinomatosis

Clinical Cancer Research

Volumn 21, Issue 1, 2015, Pages 68-76

  Reiss, Kim A ^a   Herman, Joseph M ^a   Zahurak, Marianna ^a   Brade, Anthony ^b   Dawson, Laura A ^b   Scardina, Angela ^a   Joffe, Caitlin ^a   Petito, Emily ^a   Hacker Prietz, Amy ^a   Kinders, Robert J ^c   Wang, Lihua ^c   Chen, Alice ^c   Temkin, Sarah ^d   Horiba, Naomi ^d   Siu, Lillian L ^b   Azad, Nilofer S ^a  

^a JOHNS HOPKINS UNIVERSITY   (United States)

^b PRINCESS MARGARET HOSPITAL   (Canada)

^c NATIONAL CANCER INSTITUTE   (United States)

^d UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GAMMA H2AX; HISTONE H2AX; UNCLASSIFIED DRUG; VELIPARIB; BENZIMIDAZOLE DERIVATIVE;

ABDOMINAL CRAMP; ABDOMINAL PAIN; ADULT; ADVANCED CANCER; ADVERSE OUTCOME; AGED; ANEMIA; ANOREXIA; ARTICLE; ASCITES; BLOATING; CANCER RADIOTHERAPY; CIRCULATING TUMOR CELL; CLINICAL ARTICLE; CONSTIPATION; CONTROLLED STUDY; COUGHING; DEHYDRATION; DIARRHEA; DIZZINESS; DOSE RESPONSE; DRUG DOSE ESCALATION; DRUG EFFICACY; DRY EYE; DYSGEUSIA; DYSPEPSIA; DYSPNEA; FATIGUE; FEMALE; FLATULENCE; HEADACHE; HUMAN; HYPOCALCEMIA; HYPOMAGNESEMIA; LEG EDEMA; LEUKOPENIA; LYMPHOCYTOPENIA; MALE; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUROPATHY; NEUTROPENIA; OUTCOME ASSESSMENT; OVARY CANCER; OVERALL SURVIVAL; PERITONEUM CANCER; PHASE 1 CLINICAL TRIAL; PNEUMONIA; PROGRESSION FREE SURVIVAL; PRURITUS; QUALITY OF LIFE; QUESTIONNAIRE; RADIATION DOSE FRACTIONATION; RASH; SKIN INFECTION; SMALL INTESTINE OBSTRUCTION; SOLID TUMOR; THROMBOCYTOPENIA; UTERINE TUBE TUMOR; VAGINITIS; VOMITING; ADVERSE DRUG REACTION; CARCINOMA; CLINICAL TRIAL; DISEASE FREE SURVIVAL; MIDDLE AGED; MULTIMODALITY CANCER THERAPY; OVARIAN NEOPLASMS; PATHOLOGY; PERITONEAL NEOPLASMS;

ADULT; AGED; BENZIMIDAZOLES; CARCINOMA; COMBINED MODALITY THERAPY; DISEASE-FREE SURVIVAL; DOSE FRACTIONATION; DRUG-RELATED SIDE EFFECTS AND ADVERSE REACTIONS; FEMALE; HUMANS; MALE; MIDDLE AGED; OVARIAN NEOPLASMS; PERITONEAL NEOPLASMS;

EID: 84920671472     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-14-1552     Document Type: Article

References (47)

1. Franko J, Shi Q, Goldman CD, Pockaj BA, Nelson GD, Goldberg RM, et al. Treatment of colorectal peritoneal carcinomatosis with systemic chemotherapy: a pooled analysis of north central cancer treatment group phase III trials N9741 and N9841. J Clin Oncol 2012;30:263-7.
2. Klaver YL, Lemmens VE, Nienhuijs SW, Luyer MD, de Hingh IH. Peritoneal carcinomatosis of colorectal origin: incidence, prognosis and treatment options. World J Gastroenterol 2012;18:5489-94.
3. Thomassen I, van Gestel YR, Lemmens VE, de Hingh IH. Incidence, prognosis, and treatment options for patientswith synchronous peritoneal carcinomatosis and liver metastases from colorectal origin. Dis Colon Rectum 2013;56:1373-80.
4. Goldberg N, Peschel RE. Postoperative abdominopelvic radiation therapy for ovarian cancer. Int J Radiat Oncol Biol Phys 1988;14:425-9.
5. Hruby G, Bull CA, Langlands AO, Gebski V. WART revisited: the treatment of epithelial ovarian cancer by whole abdominal radiotherapy. Australas Radiol 1997;41:276-80.
6. Lindner H, Willich N, Atzinger A, Schubert-Fritschle G. [Postoperative adjuvant whole abdomen irradiation in ovarian cancer]. Onkologie 1990;13:260-7.
7. Macbeth FR, Macdonald H, Williams CJ. Total abdominal and pelvic radiotherapy in the management of early stage ovarian carcinoma. Int J Radiat Oncol Biol Phys 1988;15:353-8.
8. Short SC, Joiner MC. Cellular response to low-dose irradiation. Clin Oncol (R Coll Radiol) 1998;10:73-7.
9. Smith H. Quantifying radiation risks. Radiat Prot Dosimetry 1999;86:259-62.
10. Regine WF, Hanna N, Garofalo MC, Doyle A, Arnold S, Kataria R, et al. Low-dose radiotherapy as a chemopotentiator of gemcitabine in tumors of the pancreas or small bowel: a phase I study exploring a new treatment paradigm. Int J Radiat Oncol Biol Phys 2007;68:172-7.
11. Kunos CA, Sill MW, Buekers TE, Walker JL, Schilder JM, Yamada SD, et al. Low-dose abdominal radiation as a docetaxel chemosensitizer for recurrent epithelial ovarian cancer: a phase I study of the Gynecologic Oncology Group. Gynecol Oncol 2011;120:224-8.
12. Petermann E, Keil C, Oei SL. Importance of poly(ADP-ribose) polymerases in the regulation of DNA-dependent processes. Cell Mol Life Sci 2005;62:731-8.
13. Hakme A, Wong HK, Dantzer F, Schreiber V. The expanding field of poly (ADP-ribosyl)ation reactions. 'Protein Modifications: Beyond the Usual Suspects' Review Series. EMBO Rep 2008;9:1094-100.
14. D'Amours D, Desnoyers S, D'Silva I, Poirier GG. Poly(ADP-ribosyl)ation reactions in the regulation of nuclear functions. BiochemJ 1999;342:249-68.
15. Ame JC, Spenlehauer C, de Murcia G. The PARP superfamily. Bioessays 2004;26:882-93.
16. Bryant HE, Schultz N, Thomas HD, Parker KM, Flower D, Lopez E, et al. Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase. Nature 2005;434:913-7.
17. Chalmers AJ. Poly(ADP-ribose) polymerase-1 and ionizing radiation: sensor, signaller and therapeutic target. Clin Oncol (R Coll Radiol) 2004;16:29-39.
18. Gelmon KA, Tischkowitz M, Mackay H, Swenerton K, Robidoux A, Tonkin K, et al. Olaparib in patients with recurrent high-grade serous or poorly differentiated ovarian carcinoma or triple-negative breast cancer: a phase 2, multicentre, open-label, non-randomised study. Lancet Oncol 2011;12:852-61.
19. Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 2000;92:205-16.
20. Alderson T. New targets for cancer chemotherapy-poly(ADP-ribosylation) processing and polyisoprenemetabolism. Biol Rev Camb Philos Soc 1990;65:623-41.
21. Chalmers AJ. The potential role and application of PARP inhibitors in cancer treatment. Br Med Bull 2009;89:23-40.
22. Farmer H, McCabe N, Lord CJ, Tutt AN, Johnson DA, Richardson TB, et al. Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy. Nature 2005;434:917-21.
23. Fong PC, Boss DS, Yap TA, Tutt A, Wu P, Mergui-Roelvink M, et al. Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers. N Engl J Med 2009;361:123-34.
24. Ang JE, Gourley C, Powell CB, High H, Shapira-Frommer R, Castonguay V, et al. Efficacy of chemotherapy in BRCA1/2 mutation carrier ovarian cancer in the setting of PARP inhibitor resistance: a multi-institutional study. Clin Cancer Res 2013;19:5485-93.
25. Tentori L, Leonetti C, Scarsella M, Muzi A, Mazzon E, Vergati M, et al. Inhibition of poly(ADP-ribose) polymerase prevents irinotecan-induced intestinal damage and enhances irinotecan/temozolomide efficacy against colon carcinoma. FASEB J 2006;20:1709-11.
26. Chalmers AJ, Lakshman M, Chan N, Bristow RG. Poly(ADP-ribose) polymerase inhibition as a model for synthetic lethality in developing radiation oncology targets. Semin Radiat Oncol 2010;20:274-81.
27. Donawho CK, Luo Y, Luo Y, Penning TD, Bauch JL, Bouska JJ, et al. ABT-888, an orally active poly(ADP-ribose) polymerase inhibitor that potentiates DNA-damaging agents in preclinical tumor models. Clin Cancer Res 2007;13:2728-37.
28. Barazzuol L, Jena R, Burnet NG, Meira LB, Jeynes JC, Kirkby KJ, et al. Evaluation of poly (ADP-ribose) polymerase inhibitor ABT-888 combined with radiotherapy and temozolomide in glioblastoma. Radiat Oncol 2013;8:65.
29. Davidson D, Wang Y, Aloyz R, Panasci L. The PARP inhibitor ABT-888 synergizes irinotecan treatment of colon cancer cell lines. Invest New Drugs 2013;31:461-8.
30. Kummar S, Chen A, Ji J, Zhang Y, Reid JM, Ames M, et al. Phase I study of PARP inhibitor ABT-888 in combination with topotecan in adults with refractory solid tumors and lymphomas. Cancer Res 2011;71:5626-34.
31. Zhang J, Kan Y, Tian Y, Wang Z, Zhang J. Effects of poly (ADP-ribosyl) polymerase (PARP) inhibitor on cisplatin resistance & proliferation of the ovarian cancer C13∗ cells. Indian J Med Res 2013;137:527-32.
32. Calabrese CR, Almassy R, Barton S, Batey MA, Calvert AH, Canan-Koch S, et al. Anticancer chemosensitization and radiosensitization by the novel poly(ADP-ribose) polymerase-1 inhibitor AG14361. J Natl Cancer Inst 2004;96:56-67.
33. Miknyoczki SJ, Jones-Bolin S, Pritchard S, Hunter K, Zhao H, Wan W, et al. Chemopotentiation of temozolomide, irinotecan, and cisplatin activity by CEP-6800, a poly(ADP-ribose) polymerase inhibitor. Mol Cancer Ther 2003;2:371-82.
34. Nowsheen S, Bonner JA, Yang ES. The poly(ADP-Ribose) polymerase inhibitor ABT-888 reduces radiation-induced nuclear EGFR and augments head and neck tumor response to radiotherapy. Radiother Oncol 2011;99:331-8.
35. Albert JM, Cao C, Kim KW, Willey CD, Geng L, Xiao D, et al. Inhibition of poly(ADP-ribose) polymerase enhances cell death and improves tumor growth delay in irradiated lung cancer models. Clin Cancer Res 2007;13:3033-42.
36. Schaefer NG, James E, Wahl RL. Poly(ADP-ribose) polymerase inhibitors combinedwith external beam and radioimmunotherapy to treat aggressive lymphoma. Nucl Med Commun 2011;32:1046-51.
37. Dungey FA, Loser DA, Chalmers AJ. Replication-dependent radiosensitization of human glioma cells by inhibition of poly(ADP-Ribose) polymerase: mechanisms and therapeutic potential. Int J Radiat Oncol Biol Phys 2008;72:1188-97.
38. Tuli R, Surmak A, Blackford A, Leubner A, Jaffee EM, Deweese TL, et al. Effect of inhibition of poly-(ADP ribose) polymerase on gemcitabine and radiation-induced cytotoxicity of pancreatic cancer cells. J Clin Oncol 2011;29 (suppl 4; abstr 203).
39. Le Tourneau C, Lee JJ, Siu LL. Dose escalation methods in phase I cancer clinical trials. J Natl Cancer Inst 2009;101:708-20.
40. Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 2009;45:228-47.
41. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Statist Assoc 1958;53:457-81.
42. Mantel N, Haenszel W. Statistical aspects of the analysis of data from retrospective studies of disease. J Natl Cancer Inst 1959;22:719-48.
43. Cox DR. Regression models and life-tables. J R Stat Soc Series B Stat Methodol 1972;34:187-220.
44. Kummar S, Kinders R, Gutierrez ME, Rubinstein L, Parchment RE, Phillips LR, et al. Phase 0 clinical trial of the poly (ADP-ribose) polymerase inhibitor ABT-888 in patients with advanced malignancies. J Clin Oncol 2009;27:2705-11.
45. Osoba D, Rodrigues G, Myles J, Zee B, Pater J. Interpreting the significance of changes in health-related quality-of-life scores. J Clin Oncol 1998;16:139-44.
46. Kalluri R, Weinberg RA. The basics of epithelial-mesenchymal transition. J Clin Invest 2009;119:1420-8.
47. Murai J, Huang SY, Das BB, Renaud A, Zhang Y, Doroshow JH, et al. Trapping of PARP1 and PARP2 by clinical PARP inhibitors. Cancer Res 2012;72:5588-99.